A Study to Evaluate the Safety and Efficacy of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus (KALM-1)

NCT03422653 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

378

Enrollment

INDUSTRY

Sponsor class

Conditions

Uremic Pruritus

Interventions

DRUG: CR845 0.5 mcg/kg
DRUG: Placebo

Sponsor

Cara Therapeutics, Inc.